Biotransformation of glucoaurantio-obtusin towards aurantio-obtusin increases the toxicity of irinotecan through increased inhibition towards SN-38 glucuronidation

Phytotherapy Research

Volumn 28, Issue 10, 2014, Pages 1577-1580

  Yu, Jian ^a   Han, Jing Chun ^a   Gao, Ya Jie ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

herb drug interaction; irinotecan; SN 38; toxicity

Indexed keywords

FIRTECAN; IRINOTECAN; NATURAL PRODUCT; OBTUSIN; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; AURANTIO-OBTUSIN; CAMPTOTHECIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TOXICITY; DRUG TRANSFORMATION; HERB DRUG INTERACTION; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; 129 MOUSE; ANALOGS AND DERIVATIVES; ANIMAL; BIOTRANSFORMATION; METABOLISM;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; CAMPTOTHECIN; MALE; MICE, 129 STRAIN;

EID: 84908503605     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5162     Document Type: Article

References (11)

1. Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF,. 2014. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 42 (3): 301 - 317.
2. Bratton SM, Mosher CM, Khallouki F, et al. 2012. Analysis of R-and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases. J Pharmacol Exp Ther 340 (1): 46 - 55.
3. Court MH, Duan SX, von Moltke LL, et al. 2001. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299 (3): 998 - 1006.
4. Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L,. 2010. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 69 (2): 193 - 199.
5. Fujita K, Sunakawa Y, Miwa K, et al. 2011. Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos 39 (2): 161 - 164.
6. Gao CC, Cao Y, Gao X, et al. 2012. Significant inhibition of UDP-glucuronosyltransferase (UGT) 1A1 by plant flavonoid alpinetin. Lat Am J Pharm 31 (9): 1360 - 1362.
7. Liu C, Cao YF, Fang ZZ, et al. 2012. Strong inhibition of deoxyschizandrin and schisantherin A toward UDP-glucuronosyltransferase (UGT) 1A3 indicating UGT inhibition-based herb-drug interaction. Fitoterapia 83 (8): 1415 - 1419.
8. Peeters M, Price TJ, Cervantes A, et al. 2014. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25 (1): 107 - 116.
9. Richardson AJ, Laurence JM, Lam VW,. 2013. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol 24 (8): 1209 - 1217.
10. Santos A, Zanetta S, Cresteil T, et al. 2000. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6 (5): 2012 - 2020.
11. Teng Y, Nian H, Zhao H, Chen P, Wang G,. 2013. Biotransformation of baicalin to baicalein significantly strengthens the inhibition potential towards UDP-glucuronosyltransferases (UGTs) isoforms. Pharmazie 68 (9): 763 - 767.